Medoclazide

Gliclazide, the active ingredient in Medoclazide, is a second‑generation sulfonylurea presented as an oral tablet for oral use. It is used to lower blood glucose in adults with type 2 diabetes mellitus by stimulating insulin release from pancreatic β‑cells and is typically prescribed when diet, exercise, and other oral agents are insufficient.

GNH USA supplies Medoclazide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance and timely delivery.

Gliclazide is used in the management of hyperglycaemia associated with type 2 diabetes mellitus, either alone or in combination with lifestyle measures. - Type 2 diabetes mellitus: improves glycaemic control by enhancing insulin secretion from pancreatic β‑cells. - Adjunct to diet and exercise in type 2 diabetes: helps achieve target blood glucose when lifestyle measures are insufficient. - Monotherapy in newly diagnosed type 2 diabetes: provides initial glucose‑lowering effect as a first‑line oral agent.

Gliclazide may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Hypoglycaemia: mild to moderate low blood glucose episodes, especially with missed meals. - Gastrointestinal upset: nausea, abdominal discomfort or diarrhoea. - Dizziness or headache: transient sensations of light‑headedness or mild head pain. - Weight gain: modest increase in body weight due to enhanced insulin action. - Skin reactions: mild rash or pruritus.

Serious or Rare Side Effects: - Severe hypoglycaemia: profound low glucose requiring assistance. - Hemolytic anaemia: rare destruction of red blood cells. - Hepatotoxicity: elevated liver enzymes or liver injury. - Allergic reactions: anaphylaxis or severe skin eruptions.

When prescribing gliclazide, clinicians should consider several precautionary measures to minimise risk and ensure safe use. - Renal impairment: dose adjustment or avoidance in severe kidney disease. - Hepatic dysfunction: use cautiously in patients with liver disease. - Elderly patients: start with lower dose and monitor for hypoglycaemia. - Concomitant sulfonylureas: avoid combining with other agents of the same class. - Pregnancy and lactation: classified as Category B; use only if benefit outweighs risk. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Gliclazide can interact with other medicines, altering its glucose‑lowering effect or increasing adverse reactions.

Major Interactions (Avoid): - Concurrent use of other sulfonylureas or meglitinides: additive hypoglycaemia risk. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone): increase gliclazide plasma levels. - MAO‑B inhibitors: may potentiate hypoglycaemic effect.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Thiazide diuretics: can enhance hyperglycaemic effect. - Anticoagulants (warfarin): gliclazide may affect INR, requiring monitoring.